KDR and neoplasm: Using two potent tyrosine-kinase and VEGFR inhibitor, one of them approved for clinical use to treat specific tumors such as renal cell carcinoma, gastro-intestinal stromal tumors or pancreatic neuroendocrine tumors22, we further demonstrate that VEGFR inhibition impairs extravasation of circulating tumor cells by blocking the endothelial remodeling.